Genetic data: The new challenge of personalized medicine, insights for rheumatoid arthritis patients

Gene

Volumn 583, Issue 2, 2016, Pages 90-101

  Goulielmos, George N ^a   Zervou, Maria I ^a   Myrthianou, Effie ^a   Burska, Agata ^b   Niewold, Timothy B ^c   Ponchel, Frederique ^b  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c MAYO GRADUATE SCHOOL   (United States)

Author keywords

Gene polymorphisms; Genotyping technologies; Personalized medicine; Rheumatoid arthritis

Indexed keywords

ALLELISM; EXOME; GENE INTERACTION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NEXT GENERATION SEQUENCING; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; ARTHRITIS, RHEUMATOID; DATA MINING; EPISTASIS; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SEQUENCING; PATHOLOGY; PROGNOSIS; TRENDS;

ANTIRHEUMATIC AGENT;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DATA MINING; EPIGENESIS, GENETIC; EPISTASIS, GENETIC; EXOME; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PRECISION MEDICINE; PROGNOSIS; QUANTITATIVE TRAIT LOCI; RISK FACTORS;

EID: 84958213733     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2016.02.004     Document Type: Review

References (165)

1. Acosta-Colman I., Palau N., Tornero J., Fernández-Nebro A., Blanco F., González-Alvaro I., Cañete J.D., Maymó J., Ballina J., Fernández-Gutiérrez B., Olivé A., Corominas H., Erra A., Canela-Xandri O., Alonso A., López Lasanta M., Tortosa R., Julià A., Marsal S. GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis. Pharmacogenomics 2013, 14:727-734.
2. Adarichev V.A., Vermes C., Hanyecz A., Mikecz K., Bremer E.G., Glant T.T. Gene expression profiling in murine autoimmune arthritis during the initiation and progression of joint inflammation. Arthritis Res. Ther. 2005, 7:R196-R207.
3. Alamanos Y., Drosos A.A. Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev. 2005, 4:130-136.
4. Atzeni F., Benucci M., Sallì S., Dongiovanni S., Boccassini L., Sarzi-Puttini P. Different effects of biological drugs in rheumatoid arthritis. Autoimmunity 2012, 12:575-579.
5. Barton A., Eyre S., Ke X., Hinks A., Bowes J., Flynn E., Martin P., YEAR Consortium, BIRAC Consortium, Wilson A.G., Morgan A.W., Emery P., Steer S., Hocking L.J., Reid D.M., Harrison P., Wordsworth P., Thomson W., Worthington J. Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. Hum. Mol. Genet. 2009, 18:2518-2522.
6. Behrens E.M., Finkel T.H., Bradfield J.P., Kim C.E., Linton L., Casalunovo T., Frackelton E.C., Santa E., Otieno F.G., Glessner J.T., Chiavacci R.M., Grant S.F., Hakonarson H. Association of the TRAF1-C5 locus on chromosome 9 with juvenile idiopathic arthritis. Arthritis Rheum. 2008, 58:2206-2207.
7. Berkun Y., Levartovsky D., Rubinow A., Orbach H., Aamar S., Grenader T., Abou Atta I., Mevorach D., Friedman G., Ben-Yehuda A. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis. 2004, 63:1227-1231.
8. Bohanec Grabar P., Rozman B., Tomsic M., Suput D., Logar D., Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur. J. Clin. Pharmacol. 2008, 64:871-876.
9. Bottini N., Musumeci L., Alonso A., Rahmouni S., Nika K., Rostamkhani M., MacMurray J., Meloni G.F., Lucarelli P., Pellecchia M., Eisenbarth G.S., Comings D., Mustelin T. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat. Genet. 2004, 36:337-338.
10. Bowes J.D., Potter C., Gibbons L.J., Hyrich K., Plant D., Morgan A.W., Wilson A.G., Isaacs J.D., Worthington J., Barton A., BRAGGSS Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet. Genomics 2009, 19:319-323.
11. Briggs F.B.S., Ramsay P.P., Madden E., Norris J.M., Holers V.M., Mikuls T.R., Sokka T., Seldin M.F., Gregersen P.K., Criswell L.A., Barcellos L.F. Supervised machine learning and logistic regression identifies novel epistatic risk factors with PTPN22 for rheumatoid arthritis. Genes Immun. 2010, 11:199-208.
12. Bukhari M., Thomson W., Naseem H., Bunn D., Silman A., Symmons D., Barton A. The performance of anti-cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: results from the Norfolk Arthritis Register. Arthritis Rheum. 2007, 56:2929-2935.
13. Burska A.N., Roget K., Blits M., Soto Gomez L., van de Loo F., Hazelwood L.D., Verweij C., Rowe A., Goulielmos G.N., van Baarsen L.G.M., Ponchel F. Gene expression analysis in RA: towards personalised medicine. Pharmacogenomics J. 2014, 14:93-106.
14. Bozina N., Bradamante V., Lovrić M. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh. Hig. Rada Toksikol. 2009, 60:217-242.
15. Bustin S.A. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 2000, 25:169-193.
16. Cannon G.W., Woods M.L., Clayton F., Griffiths M.M. Induction of arthritis in DA rats by incomplete Freund's adjuvant. J. Rheumatol. 1993, 20:7-11.
17. Carr D.F., Alfirevic A., Pirmohamed M. Pharmacogenomics: current state-of-the-art. Genes (Basel) 2014, 5:430-443.
18. Cobb J.E., Plant D., Flynn E., Tadjeddine M., Dieudé P., Cornélis F., Ärlestig L., Dahlqvist S.R., Goulielmos G., Boumpas D.T., Sidiropoulos P., Krintel S.B., Ørnbjerg L.M., Hetland M.L., Klareskog L., Haeupl T., Filer A., Buckley C.D., Raza K., Witte T., Schmidt R.E., FitzGerald O., Veale D., Eyre S., Worthington J. Identification of the tyrosine-protein phosphatase non-receptor type 2 (PTPN2) as a rheumatoid arthritis susceptibility locus in Europeans. PLoS One 2013, 8:e66456.
19. Coffey A.J., Kokocinski F., Calafato M.S., Scott C.E., Palta P., Drury E., Joyce C.J., Leproust E.M., Harrow J., Hunt S., Lehesjoki A.E., Turner D.J., Hubbard T.J., Palotie A. The GENCODE exome: sequencing the complete human exome. Eur. J. Hum. Genet. 2011, 19:827-831.
20. Cortes A., Brown M.A. Promise and pitfalls of the immunochip. Arthritis Res. Ther. 2011, 13:101. (Review).
21. Consoli L., Lefèvre A., Zivy M., de Vienne D., Damerval C. QTL analysis of proteome and transcriptome variations for dissecting the genetic architecture of complex traits in maize. Plant Mol. Biol. 2002, 48:575-581.
22. Costenbader K.H., Feskanich D., Mandl L.A., Karlson E.W. Smoking intensity, duration, and cessation, and the risk of rheumatoid arthritis in women. Am. J. Med. 2006, 119(503):e501-e509.
23. Coulthard L.R., Taylor J.C., Eyre S., Biologics in Rheumatoid Arthritis Genetics and Genomics, Robinson J.I., Wilson A.G., Isaacs J.D., Hyrich K., Emery P., Barton A., Barrett J.H., Morgan A.W., McDermott M.F. Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann. Rheum. Dis. 2011, 70:98-103.
24. Criswell L.A., Lum R.F., Turner K.N., Woehl B., Zhu Y., Wang J., Tiwari H.K., Edberg J.C., Kimberly R.P., Moreland L.W., Seldin M.F., Bridges S.L.Jr. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum. 2004, 50:2750-2756.
25. Cui J., Saevarsdottir S., Thomson B., Padyukov L., van der Helm-van Mil A.H., Nititham J., Hughes L.B., de Vries N., Raychaudhuri S., Alfredsson L., Askling J., Wedrén S., Ding B., Guiducci C., Wolbink G.J., Crusius J.B., van der Horst-Bruinsma I.E., Herenius M., Weinblatt M.E., Shadick N.A., Worthington J., Batliwalla F., Kern M., Morgan A.W., Wilson A.G., Isaacs J.D., Hyrich K., Seldin M.F., Moreland L.W., Behrens T.W., Allaart C.F., Criswell L.A., Huizinga T.W., Tak P.P., Bridges S.L., Toes R.E., Barton A., Klareskog L., Gregersen P.K., Karlson E.W., Plenge R.M. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum. 2010, 62:1849-1861.
26. Daha N.A., Toes R.E.M. Rheumatoid arthritis: are ACPA-positive and ACPA-negative RA the same disease?. Nat. Rev. Rheumatol. 2011, 7:202-203.
27. Daha N.A., Lie B.A., Trouw L.A., Stoeken G., Schonkeren J.J., Ding B., Kvien T.K., Schilham M.W., Padyukov L., Huizinga T.W., Toes R. Novel genetic association of the VTCN1 region with rheumatoid arthritis. Ann. Rheum. Dis. 2012, 71:567-571.
28. Daïen C.I., Fabre S., Rittore C., Soler S., Daïen V., Tejedor G., Cadart D., Molinari N., Daurès J.P., Jorgensen C., Touitou I. TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis. Joint Bone Spine 2012, 79:471-475.
29. Davila L., Ranganathan P. Pharmacogenetics: implications for therapy in rheumatic diseases. Nat. Rev. Rheumatol. 2011, 7:537-550.
30. De Rooy D.P., Yeremenko N.G/., Wilson A.G., Knevel R., Lindqvist E., Saxne T., Krabben A., Leijsma M.K., Daha N.A., Tsonaka S., Zhernakova A., Houwing-Duistermaat J.J., Huizinga T.W., Toes R.E., Baeten D.L., Brouwer E., van der Helm-van Mil A.H. Genetic studies on components of the wnt signalling pathway and the severity of joint destruction in rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72:769-775.
31. de Rooy D.P., Zhernakova A., Tsonaka R., Willemze A., Kurreeman B.A., Trynka G., van Toorn L., Toes R.E., Huizinga T.W., Houwing-Duistermaat J.J., Gregersen P.K., van der Helm-van Mil A.H. A genetic variant in the region of MMP-9 is associated with serum levels and progression of joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 2014, 73:1163-1169.
32. de Rooy D.P., Tsonaka R., Andersson M.L., Forslind K., Zhernakova A., Frank-Bertoncelj M., de Kovel C.G., Koeleman B.P., van der Heijde D.M., Huizinga T.W., Toes R.E., Houwing-Duistermaat J.J., Ospelt C., Svensson B., van der Helm-van Mil A.H. Genetic factors for the severity of ACPA-negative rheumatoid arthritis in 2 cohorts of early disease: a genome-wide study. J. Rheumatol. 2015, 42:1383-1391.
33. De Vries R.R., van der Woude D., Houwing J.J., Toes R.E. Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end?. Ann. Rheum. Dis. 2011, 70(Suppl. 1):i51-i54. (Review).
34. Dervieux T., Kremer J., Lein D.O., Capps R., Barham R., Meyer G., Smith K., Caldwell J., Furst D.E. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics 2004, 14:733-739.
35. Detert J., Pischon N., Burmester G.R., Buttgereit F. The association between rheumatoid arthritis and periodontal disease. Arthritis Res. Ther. 2010, 12:218. (Review).
36. Di Giuseppe D., Orsini N., Alfredsson L., Askling J., Wolk A. Arthritis Res. Ther. 2013, 15:R56.
37. Drmanac R., Sparks A.B., Callow M.J., Halpern A.L., Burns N.L., Kermani B.G., Carnevali P., Nazarenko I., Nilsen G.B., Yeung G., Dahl F., Fernandez A., Staker B., Pant K.P., Baccash J., Borcherding A.P., Brownley A., Cedeno R., Chen L., Chernikoff D., Cheung A., Chirita R., Curson B., Ebert J.C., Hacker C.R., Hartlage R., Hauser B., Huang S., Jiang Y., Karpinchyk V., Koenig M., Kong C., Landers T., Le C., Liu J., McBride C.E., Morenzoni M., Morey R.E., Mutch K., Perazich H., Perry K., Peters B.A., Peterson J., Pethiyagoda C.L., Pothuraju K., Richter C., Rosenbaum A.M., Roy S., Shafto J., Sharanhovich U., Shannon K.W., Sheppy C.G., Sun M., Thakuria J.V., Tran A., Vu D., Zaranek A.W., Wu X., Drmanac S., Oliphant A.R., Banyai W.C., Martin B., Ballinger D.G., Church G.M., Reid C.A. Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. Science 2010, 327:78-81.
38. Dziedziejko V., Kurzawski M., Safranow K., Chlubek D., Pawlik A. The effect of ESR1 and ESR2 gene polymorphisms on the outcome of rheumatoid arthritis treatment with leflunomide. Pharmacogenomics 2010, 12:41-47.
39. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
40. Evans W.E., Relling M.V. Moving towards individualized medicine with pharmacogenomics. Nature 2004, 429:464-468.
41. Eyre S., Bowes J., Diogo D., Lee A., Barton A., Martin P., Zhernakova A., Stahl E., Viatte S., McAllister K., Amos C.I., Padyukov L., Toes R.E., Huizinga T.W., Wijmenga C., Trynka G., Franke L., Westra H.J., Alfredsson L., Hu X., Sandor C., de Bakker P.I., Davila S., Khor C.C., Heng K.K., Andrews R., Edkins S., Hunt S.E., Langford C., Symmons D., Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Wellcome Trust Case Control Consortium, Concannon P., Onengut-Gumuscu S., Rich S.S., Deloukas P., Gonzalez-Gay M.A., Rodriguez-Rodriguez L., L.Ärlsetig McAllister, Martin J., Rantapää-Dahlqvist S., Plenge R.M., Raychaudhuri S., Klareskog L., Gregersen P.K., Worthington J. High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat. Genet. 2012, 44:1336-1340.
42. Feinberg A.P. Epigenomics reveals a functional genome anatomy and a new approach to common disease. Nat. Biotechnol. 2010, 28:1049-1052.
43. Gamazon E.R., Huang R.S., Cox N.J., Dolan M.E. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl. Acad. Sci. 2010, 107:9287-9292.
44. Gan R.W., Trouw L.A/., Shi J., Toes R.E., Huizinga T.W., Demoruelle M.K., Kolfenbach J.R., Zerbe G.O., Deane K.D., Edison J.D., Gilliland W.R., Norris J.M., Holers V.M. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J. Rheumatol. 2015, 42:572-579.
45. Gao L., Emond M.J., Louie T., Cheadle C., Berger A.E., Rafaels N., Vergara C., Kim Y., Taub M.A., Ruczinski I., Mathai S.C., Rich S.S., Nickerson D.A., Hummers L.K., Bamshad M.J., Hassoun P.M., Mathias R.A., National Heart, Lung, and Blood Institute GO Exome Sequencing Project, Barnes K.C. Identification of rare variants in ATP8B4 as a risk factor for systemic sclerosis by whole-exome sequencing. Arthritis Rheumatol. 2016, 68:191-200.
46. Gilissen C., Hoischen A., Brunner H.G., Veltman J.A. Disease gene identification strategies for exome sequencing. Eur. J. Hum. Genet. 2012, 20:490-497.
47. Goetz M.P., Kamal A., Ames M.M. Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response. Clin. Pharmacol. Ther. 2008, 83:160-166.
48. González-Recio O., de Maturana E.L., Vega A.T., Engelman C.D., Broman K.W. Detecting single-nucleotide polymorphism by single-nucleotide polymorphism interactions in rheumatoid arthritis using a two-step approach with machine learning and a Bayesian threshold least absolute shrinkage and selection operator (LASSO) model. BMC Proc. 2009, 3(Suppl. 7):S63.
49. Gravina M.T., Lin J.H., Levine S.S. Lane-by-lane sequencing using Illumina's genome analyzer II. Biotechniques 2013, 54:265-269.
50. Gray S.G. Perspectives on epigenetic-based immune intervention for rheumatic diseases. Arthritis Res. Ther. 2013, 15:207.
51. Gregersen P.K., Olsson L.M. Recent advances in the genetics of autoimmune disease. Annu. Rev. Immunol. 2009, 27:363-391. (Review).
52. Green E.D., Guyer M.S. Charting a course for genomic medicine from base pairs to bedside. Nature 2011, 470:204-213.
53. Gurwitz D., McLeod H.L. Genome-wide studies in pharmacogenomics: harnessing the power of extreme phenotypes. Pharmacogenomics 2013, 14:337-339.
54. Gurwitz D., Pirmohamed M. Pharmacogenomics: the importance of accurate phenotypes. Pharmacogenomics 2010, 11:469-470.
55. Hardy J., Singleton A. Genomewide association studies and human disease. N. Engl. J. Med. 2009, 360:1759-1768.
56. Harper A.R., Topol E.J. Pharmacogenomics in clinical practice and drug development. Nat. Biotechnol. 2012, 30:1117-1124.
57. Heap G.A., van Heel D.A. The genetics of chronic inflammatory diseases. Hum. Mol. Genet. 2009, 18:R101-R106.
58. Heinzen E.L., Depondt C., Cavalleri G.L., Ruzzo E.K., Walley N.M., Need A.C., Ge D., He M., Cirulli E.T., Zhao Q., Cronin K.D., Gumbs C.E., Campbell C.R., Hong L.K., Maia J.M., Shianna K.V., McCormack M., Radtke R.A., O'Conner G.D., Mikati M.A., Gallentine W.B., Husain A.M., Sinha S.R., Chinthapalli K., Puranam R.S., McNamara J.O., Ottman R., Sisodiya S.M., Delanty N., Goldstein D.B. Exome sequencing followed by large-scale genotyping fails to identify single rare variants of large effect in idiopathic generalized epilepsy. Am. J. Hum. Genet. 2012, 91:293-302.
59. Heliövaara M., Aho K., Aromaa A., Knekt P., Reunanen A. Smoking and risk of rheumatoid arthritis. J. Rheumatol. 1993, 20:1830-1835.
60. Herenius M.M.J., van Baarsen L.G.M., Klarenbeek P.L., Wijbrandts C.A., Canete J.D., Plenge R.M., Tak P.P., de Vries N. The BLIMP1 risk allele is associated with increased synovial inflammation in rheumatoid arthritis. Ann. Rheum. Dis. 2012, 70. 10.1136/ard.2010.148965.24 (Abstract).
61. Hinks A., Barton A., John S., Bruce I., Hawkins C., Griffiths C.E., Donn R., Thomson W., Silman A., Worthington J. Association between the PTPN22 gene and rheumatoid arthritis and juvenile idiopathic arthritis in a UK population: further support that PTPN22 is an autoimmunity gene. Arthritis Rheum. 2005, 52:1694-1699.
62. Holm H., Gudbjartsson D.F., Sulem P., Masson G., Helgadottir H.T., Zanon C., Magnusson O.T., Helgason A., Saemundsdottir J., Gylfason A., Stefansdottir H., Gretarsdottir S., Matthiasson S.E., Thorgeirsson G.M., Jonasdottir A., Sigurdsson A., Stefansson H., Werge T., Rafnar T., Kiemeney L.A., Parvez B., Muhammad R., Roden D.M., Darbar D., Thorleifsson G., Walters G.B., Kong A., Thorsteinsdottir U., Arnar D.O., Stefansson K. A rare variant in MYH6 is associated with high risk of sick sinus syndrome. Nat. Genet. 2011, 43:316-320.
63. Huizinga T.W., Amos C.I., van der Helm-van Mil A.H., Chen W., van Gaalen F.A., Jawaheer D., Schreuder G.M., Wener M., Breedveld F.C., Ahmad N., Lum R.F., de Vries R.R., Gregersen P.K., Toes R.E., Criswell L.A. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 2005, 52:3433-3438.
64. International Human Genome Sequencing Consortium Initial sequencing and analysis of the human genome. Nature 2001, 409:860-921.
65. Ionita-Laza I., Ottman R. Study designs for identification of rare disease variants in complex diseases: the utility of family-based designs. Genetics 2011, 189:1061-1068.
66. Julià A., Moore J., Miquel L., Alegre C., Barceló P., Ritchie M., Marsal S. Identification of a two-locus epistatic interaction associated with susceptibility to rheumatoid arthritis through reverse engineering and multifactor dimensionality reduction. Genomics 2007, 90:6-13.
67. Kallberg H., Padyukov L., Plenge R.M., Ronnelid J., Gregersen P.K., van der Helm-van Mil A.H., Toes R.E., Huizinga T.W., Klareskog L., Alfredsson L., Epidemiological investigation of rheumatoid arthritis study group Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 2007, 80:867-875.
68. Kariuki S.N., Ghodke-Puranik Y., Dorschner J.M., Chrabot B.S., Kelly J.A., Tsao B.P., Kimberly R.P., Alarcón-Riquelme M.E., Jacob C.O., Criswell L.A., Sivils K.L., Langefeld C.D., Harley J.B., Skol A.D., Niewold T.B. Genetic analysis of the pathogenic molecular sub-phenotype interferon alpha identifies multiple novel loci involved in systemic lupus erythematosus. Genes Immun. 2015, 6:15-23.
69. Karlson E.W., Lee I.M., Cook N.R., Manson J.E., Buring J.E., Hennekens C.H. A retrospective cohort study of cigarette smoking and risk of rheumatoid arthritis in female health professionals. Arthritis Rheum. 1999, 42:910-917.
70. Kastbom A., Cöster L., Arlestig L., Chatzidionysiou A., van Vollenhoven R.F., Padyukov L., Rantapää-Dahlqvist S., Saevarsdottir S. Influence of FCGR3A genotype on the therapeutic response to rituximab in rheumatoid arthritis: an observational cohort study. BMJ Open. 2012, 2:e001524.
71. Keenan B.T., Chibnik L.B., Cui J., Ding B., Padyukov L., Kallberg H., Bengtsson C., Klareskog L., Alfredsson L., Karlson E.W. Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis. Arthritis Rheum. 2010, 62:3196-3210.
72. Kere J. Genetics of complex disorders. Biochem. Biophys. Res. Commun. 2010, 396:143-146.
73. Khoury M.J., Feero W.G., Valdez R. Family history and personal genomics as tools for improving health in an era of evidence-based medicine. Am. J. Prev. Med. 2010, 39:184-188.
74. Kilpinen H., Dermitzakis E.T. Genetic and epigenetic contribution to complex traits. Hum. Mol. Genet. 2012, 21(R1):R24-R28. (Review).
75. Klareskog L., Lorentzen J., Padyukov L., Alfredsson L. Genes and environment in arthritis: can RA be prevented?. Arthritis Res. 2002, 4(Suppl. 3):S31-S36.
76. Klareskog L., Stolt P., Lundberg K., Källberg H., Bengtsson C., Grunewald J., Rönnelid J., Harris H.E., Ulfgren A.K., Rantapää-Dahlqvist S., Eklund A., Padyukov L., Alfredsson L. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 2006, 54:38-46.
77. Klareskog L., Catrina A.I., Paget S. Rheumatoid arthritis. Lancet 2009, 373:659-672.
78. Kleinau S., Erlandsson H., Holmdahl R., Klareskog L. Adjuvant oils induce arthritis in the DA rat. I. Characterization of the disease and evidence for an immunological involvement. J. Autoimmun. 1991, 4:871-880.
79. Knevel R., Krabben A., Brouwer E., Posthumus M.D., Wilson A.G., Lindqvist E., Saxne T., de Rooy D., Daha N., van der Linden M.P., Stoeken G., van Toorn L., Koeleman B., Tsonaka R., Zhernakova A., Houwing-Duistermaat J.J., Toes R., Huizinga T.W., van der Helm-van Mil A. Genetic variants in IL15 associate with progression of joint destruction in rheumatoid arthritis: a multicohort study. Ann. Rheum. Dis. 2012, 71:1651-1657.
80. Knevel R., de Rooy D.P., Zhernakova A., Gröndal G., Krabben A., Steinsson K., Wijmenga C., Cavet G., Toes R.E., Huizinga T.W., Gregersen P.K., van der Helm-van Mil A.H. Association of variants in IL2RA with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum. 2013, 65:1684-1693.
81. Knevel R., Krabben A., Wilson A.G., Brouwer E., Leijsma M.K., Lindqvist E., de Rooy D.P., Daha N.A., van der Linden M.P., Tsonaka S., Zhernakova A., Westra H.J., Franke L., Houwing-Duistermaat J.J., Toes R.E., Huizinga T.W., Saxne T., van der Helm-van Mil A.H. A genetic variant in granzyme B is associated with progression of joint destruction in rheumatoid arthritis. Arthritis Rheum. 2013, 65:582-589.
82. Knevel R., Klein K., Somers K., Ospelt C., Houwing-Duistermaat J.J., van Nies J.A., de Rooy D.P., de Bock L., Kurreeman F.A., Schonkeren J., Stoeken-Rijsbergen G., Helmer Q., van der Linden M.P., Kern M., Manjarrez-Orduno N., Rodriguez-Rodriquez L., Stinissen P., Huizinga T.W., Toes R.E., Gay S., Gregersen P.K., Somers V., van der Helm-van Mil A.H. Identification of a genetic variant for joint damage progression in autoantibody-positive rheumatoid arthritis. Ann. Rheum. Dis. 2014, 73:2038-2046.
83. Knevel R., de Rooy D.P., Saxne T., Lindqvist E., Leijsma M.K., Daha N.A., Koeleman B.P., Tsonaka R., Houwing-Duistermaat J.J., Schonkeren J.J., Toes R.E., Huizinga T.W., Brouwer E., Wilson A.G., van der Helm-van Mil A.H. A genetic variant in osteoprotegerin is associated with progression of joint destruction in rheumatoid arthritis. Arthritis. Res. Ther. 2014, 16:R108.
84. Krabben A., Knevel R., Huizinga T.W., Cavet G., van der Helm-van Mil A.H. Serum pyridinoline levels and prediction of severity of joint destruction in rheumatoid arthritis. J. Rheumatol. 2013, 40:1303-1306.
85. Krintel S.B., Palermo G., Johansen J.S., Germer S., Essioux L., Benayed R., Badi L., Ostergaard M., Hetland M.L. Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFalpha inhibitors in patients with rheumatoid arthritis. Pharmacogenet. Genomics 2012, 22:577-589.
86. Kumagai K., Hiyama K., Oyama T., Maeda H., Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med. 2003, 11:593-600.
87. Kurkó J., Besenyei T., Laki J., Glant T.T., Mikecz K., Szekanecz Z. Genetics of rheumatoid arthritis - a comprehensive review. Clin. Rev. Allergy Immunol. 2013, 45:170-179.
88. Kurreeman F.A., Goulielmos G.N., Alizadeh B.Z., Rueda B., Houwing-Duistermaat J., Sanchez E., Bevova M., Radstake T.R., Vonk M.C., Galanakis E., Ortego N., Verduyn W., Zervou M.I., Roep B.O., Dema B., Espino L., Urcelay E., Boumpas D.T., van den Berg L.H., Wijmenga C., Koeleman B.P., Huizinga T.W., Toes R.E., Martin J., AADEA Group, SLEGEN Consortium The TRAF1/C5 region is associated with multiple autoimmune diseases. Ann. Rheum. Dis. 2010, 69:696-699.
89. Laki J., Lundström E., Snir O., Rönnelid J., Ganji I., Catrina A.I., Bengtsson C., Saevarsdottir S., Wick M.C., Alfredsson L., Klareskog L., Padyukov L. Very high levels of anti-citrullinated protein antibodies are associated with HLA-DRB1*15 non-shared epitope allele in patients with rheumatoid arthritis. Arthritis Rheum. 2012, 64:2078-2084.
90. Lee S.H., Lee E.B., Shin E.S., Lee J.E., Cho S.H., Min K.U., Park H.W. The interaction between allelic variants of CD86 and CD40LG: a common risk factor of allergic asthma and Rheumatoid arthritis. Allergy Asthma Immunol. Res. 2014, 6:137-141.
91. Lee E.B., Fleischmann R., Hall S., Wilkinson B., Bradley J.D., Gruben D., Koncz T., Krishnaswami S., Wallenstein G.V., Zang C., Zwillich S.H., van Vollenhoven R.F., Start Investigators O.R.A.L. Tofacitinib versus methotrexate in rheumatoid arthritis. N. Engl. J. Med. 2014, 370:2377-2386.
92. Liu C., Batliwalla F., Li W., Lee A., Roubenoff R., Beckman E., Khalili H., Damle A., Kern M., Furie R., Dupuis J., Plenge R.M., Coenen M.J., Behrens T.W., Carulli J.P., Gregersen P.K. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol. Med. 2008, 14:575-581.
93. Livak K.J., Marmaro J., Todd J.A. Towards fully automated genome - wide polymorphism screening. Nat. Genet. 1995, 9:341-342.
94. MacGregor A.J., Snieder H., Rigby A.S., Koskenvuo M., Kaprio J., Aho K., Silman A.J. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 2000, 43:30-37.
95. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., Cho J.H., Guttmacher A.E., Kong A., Kruglyak L., Mardis E., Rotimi C.N., Slatkin M., Valle D., Whittemore A.S., Boehnke M., Clark A.G., Eichler E.E., Gibson G., Haines J.L., Mackay T.F., McCarroll S.A., Visscher P.M. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
96. Mardis E.R. Next-generation DNA sequencing methods. Annu. Rev. Genomics Hum. Genet. 2008, 9:387-402.
97. Martínez A., Varadé J., Márquez A., Cénit M.C., Espino L., Perdigones N., Santiago J.L., Fernández-Arquero M., de la Calle H., Arroyo R., Mendoza J.L., Fernández-Gutiérrez B., de la Concha E.G., Urcelay E. Association of the STAT4 gene with increased susceptibility for some immune-mediated diseases. Arthritis Rheum. 2008, 58:2598-2602.
98. Maxam A.M., Gilbert W. A new method for sequencing DNA. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:560-564.
99. McAllister K., Yarwood A., Bowes J., Orozco G., Viatte S., Diogo D., Hocking L.J., Steer S., Wordsworth P., Wilson A.G., Morgan A.W., Kremer J.M., Pappas D., Gregersen P., Klareskog L., Plenge R., Barton A., Greenberg J., Worthington J., Eyre S. Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. Arthritis Rheum. 2013, 65:3058-3062. UK Rheumatoid Arthritis Genetics Consortium; Rheumatoid Arthritis Consortium International.
100. McClellan K.A., Avard D., Simard J., Knoppers B.M. Personalized medicine and access to health care: potential for inequitable access?. Eur. J. Hum. Genet. 2013, 21:143-147.
101. McLaughlin H.M., Ceyhan-Birsoy O., Christensen K.D., Kohane I.S., Krier J., Lane W.J., Lautenbach D., Lebo M.S., Machini K., MacRae C.A., Azzariti D.R., Murray M.F., Seidman C.E., Vassy J.L., Green R.C., Rehm H.L., Project MedSeq A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Med. Genet. 2014, 15:134.
102. Mikuls T.R., Gould K.A., Bynoté K.K., Yu F., LeVan T.D., Thiele G.M., Michaud K.D., O'Dell J.R., Reimold A.M., Hooker R., Caplan L., Johnson D.S., Kerr G., Richards J.S., Cannon G.W., Criswell L.A., Noble J.A., Bridges S., Jr L., Hughes L., Gregersen P.K. Anticitrullinated protein antibody (ACPA) in rheumatoid arthritis: influence of an interaction between HLA-DRB1 shared epitope and a deletion polymorphism in glutathione S-transferase in a cross-sectional study. Arthritis Res. Ther. 2010, 12:R213.
103. Umicevic Mirkov M.1., Cui J., Vermeulen S.H., Stahl E.A., E.J.Toonen., Makkinje R.R., Lee A.T., Huizinga T.W., Allaart R., Barton A., X.Mariette., Miceli C.R., Criswell L.A., Tak P.P., de Vries N., Saevarsdottir S., Padyukov L., Bridges S.L., van Schaardenburg D.J., Jansen T.L., Dutmer E.A., van de Laar M.A., Barrera P., Radstake T.R., van Riel P.L., Scheffer H., Franke B., Brunner H.G., Plenge R.M., Gregersen P.K., Guchelaar H.J., Coenen M.J. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72:1375-1381.
104. Momozawa Y., Mn,i M., Nakamura K., Coppieters W., Almer S., Amininejad L., Cleynen I., Colombel J.F., de Rijk P., Dewit O., Finkel Y., Gassull M.A., Goossens D., Laukens D., Lémann M., Libioulle C., O'Morain C., Reenaers C., Rutgeerts P., Tysk C., Zelenika D., Lathrop M., Del-Favero J., Hugot J.P., de Vos M., D.Franchimont., Vermeire S., Louis E., Georges M. Resequencing of positional candidates identifies low frequency IL23R coding variants protecting against inflammatory bowel disease. Nat. Genet. 2011, 43:43-47.
105. Nejentsev S., Walker N., Riches D., Egholm M., Todd J.A. Rare variants of IFIH1, a gene implicated in antiviral responses, protect against type 1 diabetes. Science 2009, 324:387-389.
106. Nicolae D.L., Gamazon E.R., Zhang W., Duan S., Dolan M.E., Cox N.J. Trait-Associated SNPs Are More Likely to Be eQTLs: Annotation to Enhance Discovery from GWAS. PloS Genetics 2010, 6:e1000888. G. Gibson (Ed.).
107. O'Rielly D.D., Roslin N.M., Beyene J., Pope A., Rahman P. TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis. Pharmacogenomics J. 2009, 9:161-167.
108. Okada Y., Wu D., Trynka G., Raj T., Terao C., Ikari K., Kochi Y., Ohmura K., Suzuki A., Yoshida S., Graham R.R., Manoharan A., Ortmann W., Bhangale T., Denny J.C., Carroll R.J., Eyler A.E., Greenberg J.D., Kremer J.M., Pappas D.A., Jiang L., Yin J., Ye L., Su D.F., Yang J., Xie G., Keystone E., Westra H.J., Esko T., Metspalu A., Zhou X., Gupta N., Mirel D., Stahl E.A., Diogo D., Cui J., Liao K., Guo M.H., Myouzen K., Kawaguchi T., Coenen M.J., van Riel P.L., van de Laar M.A., Guchelaar H.J., Huizinga T.W., Dieudé P., Mariette X., Bridges S.L.Jr, Zhernakova A., Toes R.E., Tak P.P., Miceli-Richard C., Bang S.Y., Lee H.S., Martin J., Gonzalez-Gay M.A., Rodriguez-Rodriguez L., Rantapää-Dahlqvist S., Arlestig L., Choi H.K., Kamatani Y., Galan P., Lathrop M., RACI consortium, GARNET consortium, Eyre S., Bowes J., Barton A., de Vries N., Moreland L.W., Criswell L.A., Karlson E.W., Taniguchi A., Yamada R., Kubo M., Liu J.S., Bae S.C., Worthington J., Padyukov L., Klareskog L., Gregersen P.K., Raychaudhuri S., Stranger B.E., De Jager P.L., Franke L., Visscher P.M., Brown M.A., Yamanaka H., Mimori T., Takahashi A., Xu H., Behrens T.W., Siminovitch K.A., Momohara S., Matsuda F., Yamamoto K., Plenge R.M. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014, 506:376-381.
109. Orozco G., Hinks A., Eyre S., Ke X., Gibbons L.J., Bowes J. Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. Hum. Mol. Genet. 2009, 18:2693-2699.
110. Orozco G., Viatte S., Bowes J., Martin P., Wilson A.G., Morgan A.W., Steer S., Wordsworth P., Hocking L.J., UK Rheumatoid Arthritis Genetics Consortium, Wellcome Trust Case Control Consortium, Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate Consortium, Barton A., Worthington J., Eyre S. Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. Arthritis Rheumatol. 2014, 66:24-30.
111. Owen S.A., Hider S.L., Martin P., Bruce I.N., Barton A., Thomson W. Genetic polymorphisms in key methotrexate pathway genes are associated with response to treatment in rheumatoid arthritis patients. Pharmacogenomics J. 2013, 13:227-234.
112. Padyukov L., Seielstadm M., Ong R.T., Ding B., Rönnelid J., Seddighzadeh M., Alfredsson L., Klareskog L. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 2011, 70:259-265. Epidemiological investigation of rheumatoid Arthritis (EIRA) study group.
113. Pawlik A., Wrzesniewska J., Fiedorowicz-Fabrycy I., Gawronska Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther. 2004, 42:496-503.
114. Pawlik A., Ostanek L., Brzosko I., Dabrowska-Zamojcin E., Brzosko M., Florczak M., Gawrońska-Szklarz B. The influence of FcgammaRIIa polymorphism on rheumatoid arthritis. Pol. Arch. Med. Wewn. 2004, 112:907-910.
115. Pedersen M., Jacobsen S., Klarlund M., Pedersen B.V., Wiik A., Wohlfahrt J., Frisch M. Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res. Ther. 2006, 8:R133.
116. Pierer M., Kaltenhäuser S., Arnold S., Wahle M., Baerwald C., Häntzschel H., Wagner U. Association of PTPN22 1858 single-nucleotide polymorphism with rheumatoid arthritis in a German cohort: higher frequency of the risk allele in male compared to female patients. Arthritis Res. Ther. 2006, 8:R75.
117. Plant D., Bowes J., Potter C., Hyrich K.L., Morgan A.W., Wilson A.G., Isaacs J.D., Wellcome Trust Case Control Consortium, British Society for Rheumatology Biologics Register, Barton A. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011, 63:645-653.
118. Plant D., Prajapati R., Hyrich K.L., Morgan A.W., Wilson A.G., Isaacs J.D., Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Barton A. Biologics in rheumatoid arthritis genetics and genomics study syndicate, Barton a. Replication of association of the ptprc gene with response to anti-tumor necrosis factor therapy in a large UK cohort. Arthritis Rheum. 2012, 64:665-670.
119. Plenge R.M., Padyukov L., Remmers E.F., Purcell S., Lee A.T., Karlson E.W., Wolfe F., Kastner D.L., Alfredsson L., Altshuler D., Gregersen P.K., Klareskog L., Rioux J.D. Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4. Am. J. Hum. Genet. 2005, 77:1044-1060.
120. Plenge R.M., Seielstad M., Padyukov L., Lee A.T., Remmers E.F., Ding B., Liew A., Khalili H., Chandrasekaran A., Davies L.R., Li W., Tan A.K., Bonnard C., Ong R.T., Thalamuthu A., Pettersson S., Liu C., Tian C., Chen W.V., Carulli J.P., Beckman E.M., Altshuler D., Alfredsson L., Criswell L.A., Amos C.I., Seldin M.F., Kastner D.L., Klareskog L., Gregersen P.K. TRAF1-C5 as a risk locus for rheumatoid arthritis - a genomewide study. N. Engl. J. Med. 2007, 357:1199-1209.
121. Ponchel F., Toomes C., Bransfield K., Leong F.T., Douglas S.H., Field S.L., Bell S.M., Combaret V., Puisieux A., Mighell A.J., Robinson P.A., Inglehearn C.F., Isaacs J.D., Markham A.F. Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol. 2003, 3:18.
122. Popa O.M., Bojinca M., Bojinca V., Ciofu C., Bara C., Popa L.O. Introduction to SNP genotyping by Real-Time PCR. Popa et al. Travaux du Muséum National d'Histoire Naturelle «Grigore Antipa» LII 2009, 515-522.
123. Potter C., Hyrich K.L., Tracey A., Lunt M., Plant D., Symmons D.P., Thomson W., Worthington J., Emery P., Morgan A.W., Wilson A.G., Isaacs J., Barton A., BRAGGSS Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis. 2009, 68:69-74.
124. Potter C., Gibbons L.J., Bowes J.D., Cordell H.J., Hyrich K., Isaacs J.D., Morgan A.W., Wilson A.G., Barton A. Biologics in Rheumatoid arthritis genetics and genomics study syndicate. polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. pharmacogenet. Genomics 2010, 20:338-341.
125. Pruitt K.D., Harrow J., Harte R.A., Wallin C., Diekhans M., Maglott D.R., Searle S., Farrell C.M., Loveland J.E., Ruef B.J., Hart E., Suner M.M., Landrum M.J., Aken B., Ayling S., Baertsch R., Fernandez-Banet J., Cherry J.L., Curwen V., Dicuccio M., Kellis M., Lee J., Lin M.F., Schuster M., Shkeda A., Amid C., Brown G., Dukhanina O., Frankish A., Hart J., Maidak B.L., Mudge J., Murphy M.R., Murphy T., Rajan J., Rajput B., Riddick L.D., Snow C., Steward C., Webb D., Weber J.A., Wilming L., Wu W., Birney E., Haussler D., Hubbard T., Ostell J., Durbin R., Lipman D. The consensus coding sequence (CCDS) project: identifying a common protein-coding gene set for the human and mouse genomes. Genome Res. 2009, 19:1316-1323.
126. Rakyan V.K., Down T.A., Balding D.J., Beck S. Epigenome-wide association studies for common human diseases. Nat. Rev. Genet. 2011, 12:529-541.
127. Raychaudhuri S., Remmers E.F., Lee A.T., Hackett R., Guiducci C., Burtt N.P., Gianniny L., Korman B.D., Padyukov L., Kurreeman F.A., Chang M., Catanese J.J., Ding B., Wong S., van der Helm-van Mil A.H., Neale B.M., Coblyn J., Cui J., Tak P.P., Wolbink G.J., Crusius J.B., van der Horst-Bruinsma I.E., Criswell L.A., Amos C.I., Seldin M.F., Kastner D.L., Ardlie K.G., Alfredsson L., Costenbader K.H., Altshuler D., Huizinga T.W., Shadick N.A., Weinblatt M.E., de Vries N., Worthington J., Seielstad M., Toes R.E., Karlson E.W., Begovich A.B., Klareskog L., Gregersen P.K., Daly M.J., Plenge R.M. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat. Genet. 2008, 40:1216-1223.
128. Rivas M.A., Beaudoin M., Gardet A., Stevens C., Sharma Y., Zhang C.K., Boucher G., Ripke S., Ellinghaus D., Burtt N., Fennell T., Kirby A., Latiano A., Goyette P., Green T., Halfvarson J., Haritunians T., Korn J.M., Kuruvilla F., Lagacé C., Neale B., Lo K.S., Schumm P., Törkvist L., National Institute of Diabetes and Digestive Kidney Diseases Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC), United Kingdom Inflammatory Bowel Disease Genetics Consortium, International Inflammatory Bowel Disease Genetics Consortium, Dubinsky M.C., Brant S.R., Silverberg M.S., Duerr R.H., Altshuler D., Gabriel S., Lettre G., Franke A., D'Amato M., McGovern D.P., Cho J.H., Rioux J.D., Xavier R.J., Daly M.J. Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease. Nat. Genet. 2011, 43:1066-1073.
129. Rodriguez-Rodriguez L., Ivorra-Cortes J., Carmona F.D., Martín J., Balsa A., van Steenbergen H.W., van der Helm-van Mil A.H., González-Álvaro I., Fernandez-Gutiérrez B. PTGER4 gene variant rs76523431 is a candidate risk factor for radiological joint damage in rheumatoid arthritis patients: a genetic study of six cohorts. Arthritis Res. Ther. 2015, 17:306.
130. Ronaghi M., Karamohamed S., Pettersson B., Uhlén M., Nyrén P. Real-time DNA sequencing using detection of pyrophosphate release. Anal. Biochem. 1996, 242:8.
131. Ruyssen-Witrand A., Rouanet S., Combe B., Dougados M., Le Loët X., Sibilia J., Tebib J., Mariette X., Constantin A. Fcγ receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis. 2012, 71:875-877.
132. Ruyssen-Witrand A., Rouanet S., Combe B., Dougados M., Le Loët X., Sibilia J., Tebib J., Mariette X., Constantin A. Association between -871C>T promoter polymorphism in the B-cell activating factor gene and the response to rituximab in rheumatoid arthritis patients. Rheumatology (Oxford) 2013, 52:636-641.
133. Salazar J., Moya P., Altés A., Díaz-Torné C., Casademont J., Cerdà-Gabaroi D., Corominas H., Baiget M. Polymorphisms in genes involved in the mechanism of action of methotrexate: are they associated with outcome in rheumatoid arthritis patients?. Pharmacogenomics 2014, 15:1079-1090.
134. Sanger F., Nicklen S., Coulson A.R. DNA sequencing with chain-terminating inhibitors. Proc. Natl. Acad. Sci. U. S. A. 1977, 74:5463-5467.
135. Schork N., Murray S.S., Frazer K., Topol E.J. Common vs. rare allele hypotheses for complex disease. Curr. Opin. Genet. Dev. 2009, 19:212-219.
136. Silman A.J., MacGregor A.J., Thomson W., Holligan S., Carthy D., Farhan A., Ollier W.E. Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br. J. Rheumatol. 1993, 32:903-907.
137. Silverman G.J., Pelzek A. Rheumatoid arthritis clinical benefits from abatacept, cytokine blockers, and rituximab are all linked to modulation of memory B Cell responses. J. Rheumatol. 2014, 41:825-828.
138. Smith L.M., Sanders J.Z., Kaiser R.J., Hughes P., Dodd C., Connell C.R., Heiner C., Kent S.B., Hood L.E. Fluorescence detection in automated DNA sequence analysis. Nature 1986, 321:674-679.
139. Stolk J.N., Boerbooms A.M., de Abreu R.A., de Koning D.G., van Beusekom H.J., Muller W.H., van de Putte L.B. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998, 41:1858-1866.
140. Stolt P., Bengtsson C., Nordmark B., Lindblad S., Lundberg I., Klareskog L., Alfredsson L. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann. Rheum. Dis. 2003, 62:835-841.
141. Suzuki A., Yamada R., Chang X., Tokuhiro S., Sawada T., Suzuki M., Nagasaki M., Nakayama-Hamada M., Kawaida R., Ono M., Ohtsuki M., Furukawa H., Yoshino S., Yukioka M., Tohma S., Matsubara T., Wakitani S., Teshima R., Nishioka Y., Sekine A., Iida A., Takahashi A., Tsunoda T., Nakamura Y., Yamamoto K. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 2003, 34:395-402.
142. Sverdrup B., Källberg H., Bengtsson C., Lundberg I., Padyukov L., Alfredsson L., Klareskog L. Epidemiological investigation of Rheumatoid Arthritis Study Group. Association between occupational exposure to mineral oil and rheumatoid arthritis: results from the Swedish EIRA case-control study. Arthritis Res. Ther. 2005, 7:R1296-R1303.
143. Symmons D.P., Bankhead C.R., Harrison B.J., Brennan P., Barrett E.M., Scott D.G., Silman A.J. Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk. Engl. Arthritis Rheum. 1997, 40:1955-1961.
144. Tan R.J., Gibbons L.J., Potter C., Hyrich K.L., Morgan A.W., Wilson A.G., Isaacs J.D., BRAGGSS, A.Bartonl Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann. Rheum. Dis. 2010, 69:1029-1035.
145. Tanaka E., Taniguchi A., Urano W., Nakajima H., Matsuda Y., Kitamura Y., Saito M., Yamanaka H., Saito T., Kamatani N. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J. Rheumatol. 2002, 29:2492-2499.
146. Taylor L.H., Twigg S., Worthington J., Emery P., Morgan A.W., Wilson A.G., Teare M.D. Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis. J. Rheumatol. 2013, 40:1048-1053.
147. Thabet M.M/., Huizinga T.W., Marques R.B., Stoeken-Rijsbergen G., A.M.Bakker, Kurreeman F.A., White S.J., Toes R.E., van der Helm-van Mil A.H. Contribution of Fcgamma receptor IIIA gene 158V/F polymorphism and copy number variation to the risk of ACPA-positive rheumatoid arthritis. Ann. Rheum. Dis. 2006, 68:1775-1780.
148. The Wellcome Trust Case Control Consortium Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007, 447:661-678.
149. Tobón G.J., Youinou P., Saraux A. The environment, geo-epidemiology, and autoimmune disease: rheumatoid arthritis. Autoimmun. Rev. 2010, 9:A288-A292. (Review).
150. Tolusso B., Pietrapertosa D., Morelli A., De Santis M., Gremese E., Farina G., Carniello S.G., Del Frate M., Ferraccioli G. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics 2006, 7:683-695.
151. Umicevic Mirkov M.1., Cui J., Vermeulen S.H., Stahl E.A., E.J.Toonen., Makkinje R.R., Lee A.T., Huizinga T.W., Allaart R., Barton A., X.Mariette., Miceli C.R., Criswell L.A., Tak P.P., de Vries N., Saevarsdottir S., Padyukov L., Bridges S.L., van Schaardenburg D.J., Jansen T.L., Dutmer E.A., van de Laar M.A., Barrera P., Radstake T.R., van Riel P.L., Scheffer H., Franke B., Brunner H.G., Plenge R.M., Gregersen P.K., Guchelaar H.J., Coenen M.J. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2013, 72:1375-1381.
152. van der Helm-van Mil A.H., Huizinga T.W. Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Res. Ther. 2008, 10:205.
153. van Steenbergen H.W., Rodríguez-Rodríguez L., Berglin E., Zhernakova A., Knevel R., Ivorra-Cortés J., Huizinga T.W., Fernández-Gutiérrez B., Gregersen P.K., Rantapää-Dahlqvist S., van der Helm-van Mil A.H. A genetic study on C5-TRAF1 and progression of joint damage in rheumatoid arthritis. Arthritis Res. Ther. 2015, (2015Jan 8;17:1).
154. Verma M. Epigenome-Wide Association Studies (EWAS) in cancer. Curr. Genom. 2012, 13:308-313.
155. Verpoort K.N., van Gaalen F.A., van der Helm-van MilM A.H., Schreuder G.M., Breedveld F.C., Huizinga T.W., de Vries R.R., Toes R.E. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 2005, 52:3058-3062.
156. Viatte S., Plant D., Bowes J., Lunt M., Eyre S., Barton A., Worthington J. Genetic markers of rheumatoid arthritis susceptibility in anti-citrullinated peptide antibody negative patients. Ann. Rheum. Dis. 2012, 71:1984-1990.
157. Visser K., Goekoop-Ruiterman Y.P., de Vries-Bouwstra J.K., Ronday H.K., Seys P.E., Kerstens P.J., Huizinga T.W., Dijkmans B.A., Allaart C.F. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. Ann. Rheum. Dis. 2010, 69:1333-1337.
158. Wadelius M., Chen L.Y., Lindh J.D., Eriksson N., Ghori M.J., Bumpstead S., Holm L., McGinnis R., Rane A., Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 2009, 113:784-792.
159. Wordsworth P., Pile K.D., Buckely J.D., Lanchbury J.S., Ollier B., Lathrop M., Bell J.I. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am. J. Hum. Genet. 1992, 51:585-591.
160. Zeggini E. Next-generation association studies for complex traits. Nat. Genet. 2011, 43:287-288.
161. Zervou M.I., Mamoulakis D., Panierakis C., Boumpas D.T., Goulielmos G.N. STAT4: a risk factor for type 1 diabetes?. Hum. Immunol. 2008, 69:647-650.
162. Zervou M.I., Myrthianou E., Flouri I., Plant D., Chlouverakis G., Castro-Giner F., Rapsomaniki P., Boumpas D.T., Barton A., Sidiropoulos P., Goulielmos G.N. Genetic association of rheumatoid arthritis patients treated with anti-TNF medication: results from a homogeneous Greek population. PLoS One 2013, 8:e74375.
163. Zhernakova A., van Diemen C.C., Wijmenga C. Detecting shared pathogenesis from the shared genetics of immune-related diseases. Nat. Rev. Genet. 2009, 10:43-55.
164. Zhou V.W., Goren A., Bernstein B.E. Charting histone modifications and the functional organization of mammalian genomes. Nat. Rev. Genet. 2011, 12:7-18.
165. 1000 Genomes Project consortium Nature 2010, 467:1061-1073.